Eli Lilly’s first-quarter results underscore how branded pharma is betting on GLP-1 momentum and pipeline breadth
Lilly reported a 56% jump in first-quarter revenue and raised its full-year outlook, as the company also announced a key FDA approval for its oral GLP-1 and highlighted progress in multiple late-stage programs.